PIRAMAL PHARMA SOLUTIONS SUPPORTS THERACOSBIO WITH INTEGRATED DRUG SUBSTANCE/DRUG PRODUCT PROGRAM FOR BEXAGLIFLOZIN

TheracosBio recently received FDA approval for Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor Piramal supported TheracosBio with starting materials, active pharmaceutical ingredient (API), and oral solid dosage formulation Integrated drug development…